Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.

Winer A, Ghatalia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Deiry WS.

Oncologist. 2019 Aug 23. pii: theoncologist.2018-0686. doi: 10.1634/theoncologist.2018-0686. [Epub ahead of print]

PMID:
31444293
2.

Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.

Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, Hakimi AA, Sonpavde G, Plimack E.

J Immunother Cancer. 2019 May 28;7(1):139. doi: 10.1186/s40425-019-0621-1.

3.

First-line Immunotherapy in Metastatic Urothelial Carcinoma.

Ghatalia P, Zibelman M, Geynisman DM, Plimack ER.

Eur Urol Focus. 2019 May 15. pii: S2405-4569(19)30131-2. doi: 10.1016/j.euf.2019.04.015. [Epub ahead of print]

PMID:
31103603
4.

Update on perioperative systemic therapy for urothelial carcinoma.

Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM.

Clin Adv Hematol Oncol. 2019 Mar;17(3):176-183. Review.

PMID:
30969956
5.

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C.

J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3.

6.

Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic.

Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski LA, Slifker M, Saltzberg PD, Bubes N, Anari FM, Kasireddy V, Varshavsky A, Liu Y, Ross EA, El-Deiry WS.

Front Oncol. 2019 Jan 17;8:652. doi: 10.3389/fonc.2018.00652. eCollection 2018.

7.

Interaction of germline variants in a family with a history of early-onset clear cell renal cell carcinoma.

Nicolas E, Demidova EV, Iqbal W, Serebriiskii IG, Vlasenkova R, Ghatalia P, Zhou Y, Rainey K, Forman AF, Dunbrack RL Jr, Golemis EA, Hall MJ, Daly MB, Arora S.

Mol Genet Genomic Med. 2019 Mar;7(3):e556. doi: 10.1002/mgg3.556. Epub 2019 Jan 24.

8.

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.

Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C.

J Immunother Cancer. 2019 Jan 24;7(1):18. doi: 10.1186/s40425-018-0489-5.

9.

Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma.

Ghatalia P, Zibelman MR, Geynisman DM, Plimack ER.

Clin Adv Hematol Oncol. 2018 Oct;16(10):677-686. Review.

PMID:
30543598
10.

The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov Website.

Ghatalia P, Koenigsberg R, Pisarcik D, Handorf EA, Geynisman DM, Zibelman M.

Kidney Cancer. 2017 Nov 27;1(2):151-159. doi: 10.3233/KCA-170015.

11.

Systematic Review: ClearCode 34 - A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC).

Ghatalia P, Rathmell WK.

Kidney Cancer. 2018;2(1):23-29. doi: 10.3233/KCA-170021. Epub 2018 Mar 30.

12.

Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis.

Nam HY, Chandrashekar DS, Kundu A, Shelar S, Kho EY, Sonpavde G, Naik G, Ghatalia P, Livi CB, Varambally S, Sudarshan S.

Mol Cancer Res. 2019 Jan;17(1):84-96. doi: 10.1158/1541-7786.MCR-17-0636. Epub 2018 Aug 21.

PMID:
30131446
13.

Approved checkpoint inhibitors in bladder cancer: which drug should be used when?

Ghatalia P, Zibelman M, Geynisman DM, Plimack E.

Ther Adv Med Oncol. 2018 Jul 30;10:1758835918788310. doi: 10.1177/1758835918788310. eCollection 2018. Review.

14.

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.

Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM.

Mol Cancer Ther. 2018 Jul;17(7):1355-1364. doi: 10.1158/1535-7163.MCT-17-1299. Review.

15.

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.

Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS.

J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8.

16.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P.

Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.

17.

Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies.

Ghatalia P, Pond GR, Templeton AJ, Sonpavde G.

Clin Genitourin Cancer. 2018 Apr;16(2):e277-e287. doi: 10.1016/j.clgc.2017.12.006. Epub 2017 Dec 27. Review.

PMID:
29352714
18.

Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.

Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS.

Cancer Biol Ther. 2017 Sep 2;18(9):651-654. doi: 10.1080/15384047.2017.1356506. Epub 2017 Jul 20.

19.

Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.

Ghosh AP, Willey CD, Anderson JC, Welaya K, Chen D, Mehta A, Ghatalia P, Madan A, Naik G, Sudarshan S, Sonpavde G.

Oncotarget. 2017 Apr 25;8(17):29220-29232. doi: 10.18632/oncotarget.16352.

20.

Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.

Ghatalia P, Zibelman M, Geynisman DM, Plimack ER.

Curr Treat Options Oncol. 2017 Jan;18(1):7. doi: 10.1007/s11864-017-0458-0. Review.

PMID:
28210995
21.

Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review.

Jung K, Ghatalia P, Litwin S, Horwitz EM, Uzzo RG, Greenberg RE, Viterbo R, Geynisman DM, Kutikov A, Plimack ER, Smaldone MC, Wong YN, Bilusic M.

Clin Genitourin Cancer. 2017 Jun;15(3):e337-e343. doi: 10.1016/j.clgc.2016.09.005. Epub 2016 Sep 30. Review.

PMID:
27991416
22.

Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets.

Ghatalia P, Yang ES, Lasseigne BN, Ramaker RC, Cooper SJ, Chen D, Sudarshan S, Wei S, Guru AS, Zhao A, Cooper T, Della Manna DL, Naik G, Myers RM, Sonpavde G.

PLoS One. 2016 Aug 30;11(8):e0160924. doi: 10.1371/journal.pone.0160924. eCollection 2016.

23.

Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions.

Zibelman M, Ghatalia P, Geynisman DM, Plimack ER.

Immunotherapy. 2016 Jun;8(7):785-98. doi: 10.2217/imt-2016-0028. Review.

PMID:
27349978
24.

Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials.

Ghatalia P, Morgan CJ, Sonpavde G.

Crit Rev Oncol Hematol. 2016 Feb;98:122-36. doi: 10.1016/j.critrevonc.2015.10.018. Epub 2015 Nov 9. Review.

PMID:
26597016
25.

High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes.

Anderson JC, Willey CD, Mehta A, Welaya K, Chen D, Duarte CW, Ghatalia P, Arafat W, Madan A, Sudarshan S, Naik G, Grizzle WE, Choueiri TK, Sonpavde G.

PLoS One. 2015 Sep 25;10(9):e0139267. doi: 10.1371/journal.pone.0139267. eCollection 2015.

26.

Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials.

Ghatalia P, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G.

Crit Rev Oncol Hematol. 2015 Aug;95(2):251-63. doi: 10.1016/j.critrevonc.2015.03.006. Epub 2015 Apr 9. Review.

PMID:
25900071
27.

Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G.

Crit Rev Oncol Hematol. 2015 May;94(2):228-37. doi: 10.1016/j.critrevonc.2014.12.008. Epub 2014 Dec 19. Review.

PMID:
25577572
28.

Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Ghatalia P, Morgan CJ, Choueiri TK, Rocha P, Naik G, Sonpavde G.

Crit Rev Oncol Hematol. 2015 Apr;94(1):136-45. doi: 10.1016/j.critrevonc.2014.11.008. Epub 2014 Dec 4. Review.

PMID:
25541349
29.

Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials.

Ghatalia P, Je Y, Mouallem NE, Nguyen PL, Trinh QD, Sonpavde G, Choueiri TK.

Crit Rev Oncol Hematol. 2015 Mar;93(3):257-76. doi: 10.1016/j.critrevonc.2014.11.006. Epub 2014 Nov 27. Review.

PMID:
25523486
30.

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK.

Br J Cancer. 2015 Jan 20;112(2):296-305. doi: 10.1038/bjc.2014.564. Epub 2014 Nov 6.

31.

Reversible blindness in cryptococcal meningitis with normal intracranial pressure: case report and review of the literature.

Ghatalia PA, Vick A, Vattoth S, Roberson GH, Pappas PG.

Clin Infect Dis. 2014 Jul 15;59(2):310-3. doi: 10.1093/cid/ciu216. Epub 2014 Apr 4. Review.

PMID:
24704725
32.

Primary cutaneous marginal zone lymphoma associated with juxta-articular fibrotic nodules in a teenager.

Ghatalia P, Porter J, Wroblewski D, Carlson JA.

J Cutan Pathol. 2013 May;40(5):477-84. doi: 10.1111/cup.12102. Epub 2013 Mar 8.

PMID:
23578183
33.

Multifunctional nanoparticles for prostate cancer therapy.

Salvador-Morales C, Gao W, Ghatalia P, Murshed F, Aizu W, Langer R, Farokhzad OC.

Expert Rev Anticancer Ther. 2009 Feb;9(2):211-21. doi: 10.1586/14737140.9.2.211. Review. Erratum in: Expert Rev Anticancer Ther. 2009 Nov;9(11):1698-9.

PMID:
19192959

Supplemental Content

Loading ...
Support Center